BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration

Benha University20 enrolled

Overview

Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA)

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Dystrophy, Retinal

Interventions

Brolucizumab-DbllDRUG

intravitreal injection of Brolucizumab (BEOVU)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Dystrophy-Related macular neovascularization degeneration Exclusion Criteria: * age related macular degeneration , other causes of macular neovascularization degeneration

Locations (1)

INMC

Abu Dhabi, United Arab Emirates

RECRUITING

Outcomes

Primary Outcomes

Best corrected visual acuity (BCVA)

Change in BCVA in LOG MARS(logarithm minimum angle of resolution)

Time frame: 12 months

Secondary Outcomes

optical coherence tomography (OCT) foveal thickness

change in foveal thickness measured in micrometer

Time frame: 12 months

Central Contacts

Tarek R Elhamaky, MD

CONTACT

+97126324200 thamaky@ibnnafees.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.